Key Takeaways
- Global markets surged as the U.S. and Iran reached a landmark peace deal to end hostilities and reopen the Strait of Hormuz, significantly easing geopolitical risk.
- AstraZeneca (AZN) received FDA Priority Review for Ultomiris in treating a rare kidney disease, with a regulatory decision expected in Q4 2026.
- Australia’s ASX 200 closed 1.3% higher at 8,914.0, hitting its highest level since April as commodity prices rose and bond yields fell.
- European economic data showed a mixed picture, with Swedish unemployment jumping to 9.4% while German wholesale prices fell 0.6% month-on-month.
- Sovereign bond yields dropped across the Eurozone and Australia, reflecting a shift in investor sentiment toward riskier assets following the Middle East de-escalation.
Geopolitical Breakthrough Drives Market Optimism
Global financial markets reacted with a sharp rally on Monday following reports that the United States and Iran have finalized a peace deal. The agreement, announced by President Donald Trump, includes an immediate ceasefire and the reopening of the Strait of Hormuz, a critical maritime artery for global oil supplies.
In response, oil prices tumbled more than 4%, easing global inflation concerns and allowing investors to price in a more dovish path for central bank interest rates. The U.S. Dollar touched a 10-day low against major peers as "safe-haven" demand receded, while the Euro and Australian Dollar posted notable gains.
AstraZeneca Gains Regulatory Momentum
AstraZeneca (AZN) announced that the U.S. FDA has accepted a supplemental Biologics License Application for Ultomiris and granted it Priority Review. The drug is being evaluated for the treatment of adults with immunoglobulin A nephropathy (IgAN), a rare inflammatory kidney disease that often leads to end-stage renal failure.
The application is supported by Phase III I CAN trial data, which demonstrated a 43.4% reduction in proteinuria compared to a placebo. If approved, Ultomiris would become the first C5 complement inhibitor available for this specific patient population, providing a significant new revenue stream for the pharmaceutical giant.
European Economic Divergence
Economic data from Europe presented a challenging outlook for the region's recovery. Sweden’s unemployment rate rose sharply to 9.4% in May, up from 8.7% in the previous month, significantly exceeding market expectations. The data highlights persistent labor market weakness despite broader signs of global stabilization.
In Germany, the Wholesale Price Index (WPI) fell 0.6% in May on a monthly basis, though it remains 5.9% higher than a year ago. Analysts attribute the monthly decline to a reduction in energy taxes, which helped offset the broader inflationary pressures seen earlier in the year.
Analyst Adjustments and Commodity Trends
In the equity markets, Deutsche Bank issued several target price revisions for major European firms. The bank lowered its target for Sanofi (SAN) to €95 from €100 and reduced its outlook for Vodafone Group (VOD) to 150p from 155p.
Meanwhile, Marubeni data revealed that aluminum stocks at key Japanese ports fell to 238,900 MT in May. This tightening of supply comes as industrial demand begins to stabilize, though traders remain cautious regarding the long-term impact of trade tariffs and shifting supply chains in the metals sector.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.